Please login to the form below
non-steroidal therapy
This page shows the latest non-steroidal therapy news and features for those working in and with pharma, biotech and healthcare.
Roche out-licenses lebrikizumab rights to Dermira
Other competition is also in the offing including GlaxoSmithKline's asthma therapy Nucala (mepolizumab) and non-steroidal anti-inflammatory tapinarof, which are both in mid-stage testing for atopic dermatitis, and
Latest news
-
FDA green light for Pfizer's eczema drug
Pfizer's blockbuster-in-waiting Eucrisa has been approved by the FDA for eczema, becoming the first non-steroidal therapy for the skin condition in more than 15 years.
-
Pfizer adds eczema drug with $5.2bn Anacor acquisition
Expands innovative products business with non-steroidal therapy Crisaborole. Pfizer has snapped up Californian biopharma company Anacor in a $5.2bn deal that gives it a late-stage eczema candidate. ... and if approved would be the first new non-steroidal
-
Novartis wins childhood arthritis indication for Ilaris in EU
Ilaris gains a new indication as a monthly subcutaneous injection in patients aged two years and older who have not responded to therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and ... The approval] represents another significant milestone in
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
